These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A phase II trial of marimastat in advanced pancreatic cancer. Evans JD, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J, Imrie CW, Brown P, Neoptolemos JP. Br J Cancer; 2001 Dec 14; 85(12):1865-70. PubMed ID: 11747327 [Abstract] [Full Text] [Related]
23. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects]. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Ann Biol Clin (Paris); 2003 Dec 14; 61(2):147-58. PubMed ID: 12702469 [Abstract] [Full Text] [Related]
24. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. J Pathol; 1997 Jul 14; 182(3):347-55. PubMed ID: 9349239 [Abstract] [Full Text] [Related]
25. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. Park MJ, Park IC, Hur JH, Kim MS, Lee HC, Woo SH, Lee KH, Rhee CH, Hong SI, Lee SH. J Neurosurg; 2002 Jul 14; 97(1):112-8. PubMed ID: 12134900 [Abstract] [Full Text] [Related]
26. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M. J Cell Biol; 2001 May 28; 153(5):893-904. PubMed ID: 11381077 [Abstract] [Full Text] [Related]
34. Leukemic cells (HL-60) produce a novel extracellular matrix-degrading proteinase that is not inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs). Dittmann KH, Lottspeich F, Ries C, Petrides PE. Exp Hematol; 1995 Feb 28; 23(2):155-60. PubMed ID: 7828672 [Abstract] [Full Text] [Related]
35. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects. Levin M, Udi Y, Solomonov I, Sagi I. Biochim Biophys Acta Mol Cell Res; 2017 Nov 28; 1864(11 Pt A):1927-1939. PubMed ID: 28636874 [Abstract] [Full Text] [Related]
36. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Steward WP, Thomas AL. Expert Opin Investig Drugs; 2000 Dec 28; 9(12):2913-22. PubMed ID: 11093361 [Abstract] [Full Text] [Related]
37. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Duffy MJ, McCarthy K. Int J Oncol; 1998 Jun 28; 12(6):1343-8. PubMed ID: 9592197 [Abstract] [Full Text] [Related]
38. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. Kobayashi K, Arimura Y, Goto A, Okahara S, Endo T, Shinomura Y, Imai K. J Pathol; 2006 Jul 28; 209(3):376-83. PubMed ID: 16552705 [Abstract] [Full Text] [Related]